Magnesium Sulfate Versus Placebo for Tocolysis in PPROM
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.
| Condition | Intervention |
|---|---|
|
Preterm Premature Rupture of Membranes |
Drug: Magnesium sulfate |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes |
- hours of latency to delivery
- maternal postpartum length of stay
- maternal infection rates
- neonatal ventilator days
- neonatal early onset infection
- neonatal length of stay
| Estimated Enrollment: | 128 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | April 2009 |
The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most studies, tocolysis was not attempted prior to the onset of labor in this group of women. The ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit administration of steroids and maternal antibiotics is based primarily upon consensus, not consistent scientific evidence.
The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis, is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and babies between 26 and 32 weeks gestation with PPROM.
Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All English and Spanish speaking women 18-45 years with PPROM and cervical dilation <4 will be eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or > 6 hours tocolysis at time of admission will be excluded.
Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2 grams/hr x 48 hrs.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- English or Spanish speaking
- preterm premature rupture of membranes
- 26 - 32.6 weeks gestation
- cervical dilation </= 4 cm
Exclusion Criteria:
- suspected intrauterine or intraamniotic infection
- > 6 hours of tocolysis prior to admission
- positive fetal lung maturity
Contacts and Locations| Contact: Lorrie A Mason, MSN | 423 826-8086 | lorrie@rocob.com |
| United States, Tennessee | |
| Regional Obstetrical Consultants | Recruiting |
| Chattanooga, Tennessee, United States, 37403 | |
| Contact: Lorrie A Mason, MSN 423-826-8086 lorrie@rocob.com | |
| Sub-Investigator: Shawn P Stallings, MD | |
| Sub-Investigator: Joseph H Kipikasa, MD | |
| Sub-Investigator: C David Adair, MD | |
| Sub-Investigator: Carlos Torres, MD | |
| Sub-Investigator: Brandon Riggan, MD | |
| Principal Investigator: | Christian M Briery, MD | Regional Obstetrical Consultants; UT Chattanooga OB-GYN Department |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00463736 History of Changes |
| Other Study ID Numbers: | 07-006 |
| Study First Received: | April 19, 2007 |
| Last Updated: | April 19, 2007 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Regional Obstetrical Consultants:
|
short term tocolysis preterm premature rupture of membranes |
Additional relevant MeSH terms:
|
Fetal Membranes, Premature Rupture Rupture Obstetric Labor Complications Pregnancy Complications Wounds and Injuries Magnesium Sulfate Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents |
Therapeutic Uses Anesthetics Central Nervous System Depressants Anti-Arrhythmia Agents Cardiovascular Agents Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Tocolytic Agents Reproductive Control Agents |
ClinicalTrials.gov processed this record on June 13, 2013